Celltrion under scrutiny in insider trading probe

It's another insider trading probe for the pharma business. South Korean regulators are investigating allegations that the CEO of Celltrion, the biosimilars developer, profited off insider knowledge. The company says it hasn't engaged in anything like insider trading but confirmed the government investigation. Report

Suggested Articles

Johnson & Johnson faces a litany of problems, but executives are clearly not concerned—at least not about the company's short-term fortunes.

This week, Goldman Sachs resurrected a burning question: How can pharma companies profit from curing patients with one-time gene and cell therapies?

CMS has determined how it'll pay for Gilead's CAR-T cancer therapy, Yescarta, for outpatient use, but hasn't yet decided on Gilead's…